NCCN Guidelines®: Insights malignant pleural mesothelioma, version 3.2016

David S Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'amico, Thomas Dilling, Michael Dobelbower, Ramaswamy Govindan, Mark Hennon, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules LinBilly W. Loo, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A Shapiro, Neelesh Sharma, Scott J. Swanson, James Stevenson, Kurt Tauer, Stephen C Yang, Kristina Gregory, Miranda Hughes

Research output: Contribution to journalReview article

Abstract

These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.

Original languageEnglish (US)
Pages (from-to)825-836
Number of pages12
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume14
Issue number7
StatePublished - Jul 1 2016

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'NCCN Guidelines®: Insights malignant pleural mesothelioma, version 3.2016'. Together they form a unique fingerprint.

  • Cite this

    Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'amico, T. A., Dilling, T., Dobelbower, M., Govindan, R., Hennon, M., Horn, L., Jahan, T. M., Komaki, R., Lackner, R. P., Lanuti, M., Lilenbaum, R., ... Hughes, M. (2016). NCCN Guidelines®: Insights malignant pleural mesothelioma, version 3.2016. JNCCN Journal of the National Comprehensive Cancer Network, 14(7), 825-836.